In an interview conducted during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020, Saad Usmani, MD, MBBS, MBA, of the Levine Cancer Institute in Charlotte, NC, discusses recent treatment updates in multiple myeloma. The CELMoDs iberdomide and CC-92480 have demonstrated molecular activity as monotherapies and in combination with dexamethasone. Selinexor has shown potential, with the BOSTON trial designed to investigate selinexor plus dexamethasone and bortezomib in heavily pretreated patients. Promising data have been presented on the peptide-drug conjugate melflufen and the antibody-drug conjugate belantamab mafodotin.